P‐tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study

Evaluation of the clinical utility of plasma tau phosphorylated at position 217 (p-tau217) for identifying Alzheimer's disease pathology has been limited.In this study, the impact of p-tau testing on health care providers' diagnostic thinking in patients under evaluation for cognitive impairment was assessed.When the result was inconsistent with the working diagnosis, a change in the working diagnosis was observed in 70.5% of tested patients.When the result was consistent, diagnostic confidence increased by 15.7%.P-tau217 testing demonstrated clinical utility by changing the working diagnosis, increasing diagnostic confidence, and altering intended patient management.